Overview
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
Status:
Completed
Completed
Trial end date:
2003-01-01
2003-01-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin, paclitaxel, and carboplatin in treating patients who have primary stage III, stage IV, or recurrent endometrial cancer.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Memorial Sloan Kettering Cancer CenterCollaborator:
National Cancer Institute (NCI)Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Doxorubicin
Liposomal doxorubicin
Paclitaxel
Criteria
DISEASE CHARACTERISTICS:- Histologically proven primary stage III or IV or recurrent endometrial cancer
- Bidimensionally measurable disease by x-ray, CT scan, MRI scan, or physical exam
- Sole site may be within a previously irradiated area if documented disease
progression since prior radiotherapy
PATIENT CHARACTERISTICS:
Age:
- Adult
Performance status:
- Karnofsky 70-100%
Life expectancy:
- At least 12 weeks
Hematopoietic:
- Absolute neutrophil count greater than 1,000/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin, SGOT, and alkaline phosphatase no greater than 1.5 times normal
Renal:
- Creatinine no greater than 1.8 mg/dL
Cardiovascular:
- Left ventricular ejection fraction at least 50%
Other:
- No active uncontrolled infection
- No greater than grade II neuropathy
- No other active malignancy
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior doxorubicin
- Greater than 6 months since prior paclitaxel, carboplatin, or other platinum compounds
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
- At least 4 weeks since prior radiotherapy and recovered
Surgery:
- Not specified